Fighting amyotrophic lateral sclerosis by protecting the liver? A prospective cohort study

Multiparametric MRI, including cT1, was used to non-invasively monitor treatment response to lanifibranor in NASH. cT1 was significantly reduced after 24 weeks of treatment compared to placebo, indicating reduced hepatic fibroinflammation. Moreover, cT1 change was associated with histologic improvements in SAF activity score, supporting cT1 as a sensitive, non-invasive imaging biomarker for assessing therapeutic response in NASH